Hoxton Ventures joins NVIDIA’s £2 billion UK artificial intelligence investment

Hoxton Ventures is participating in NVIDIA's £2 billion programme to expand capital and compute for British founders, aiming to strengthen the UK's role in artificial intelligence. The collaboration brings together leading venture firms to support startups across London, Oxford, Cambridge and Manchester.

LONDON, Sept. 18, 2025 – Hoxton Ventures announced it is participating in NVIDIA’s landmark £2 billion investment to bolster the United Kingdom’s artificial intelligence ecosystem. The initiative pools capital and compute resources from NVIDIA alongside venture partners including Accel, Air Street Capital, Balderton and Phoenix Court to expand access to both funding and high-performance computing for British founders. The collaboration is intended to accelerate next-generation artificial intelligence companies and support global expansion by UK-based startups.

The partners say the investment will address long-standing constraints in the UK market, including limited access to supercomputing power, constrained venture capital funding outside London, and barriers between academia and entrepreneurship. The programme is explicitly targeted at innovation hubs across London, Oxford, Cambridge and Manchester, as well as other regions. Hoxton framed the move as a way to combine local expertise with global scale to give founders the capital, compute and infrastructure needed to build transformative businesses.

Hoxton positioned the commitment as a continuation of its decade-long focus on early-stage technology companies. The firm cited portfolio companies and deeptech spinouts as examples of the UK’s research-to-market pipeline, naming CuspAI, Machenta, Milvus Advanced and Universal Quantum, and listing broader portfolio companies such as Deliveroo, Darktrace, Preply, Avantia Law, Finster, Kitt, Peptone and Skin Analytics. The release also highlights a current collaboration between Peptone and NVIDIA to develop an artificial intelligence model that predicts the shape of disordered proteins, a class of biology that traditional experimental techniques have struggled to resolve. Hussein Kanji, founder and managing partner at Hoxton Ventures, said the partnership aims to ensure Britain’s brightest founders have the resources to build globally transformative businesses.

70

Impact Score

CDC vaccine guidance meeting raises alarm

A Senate hearing and a pivotal advisory vote have exposed turmoil at the CDC over vaccine guidance, with former leaders warning that staff are being told to turn their backs on scientific evidence and advisers voting to stop recommending the MMRV vaccine for children under four.

Contact Us

Got questions? Use the form to contact us.

Contact Form

Clicking next sends a verification code to your email. After verifying, you can enter your message.